Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
N/A | mepolizumab | Eosinophilic Granulomatosis with Polyangiitis | Active | |||
N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active | |||
Tagrisso | osimertinib | Non-small cell lung cancer | Active | |||
Keytruda | pembrolizumab | Biliary tract carcinoma | Active | |||
Repatha | evolocumab | Primary hyperlipidemia | Active | |||
Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Active | |||
Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
Orgovyx | relugolix | Advanced prostate cancer | Active | |||
Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active |